



4 June 2008

Company Announcements Office
Australian Securities Exchange

Appointment of CEO

Nanosonics Limited (ASX:NAN) is pleased to announce that it has appointed Mr David Radford as Chief Executive Officer and Company Director, effective from 16th June 2008.

David has more than twenty years experience in the medical device and health care industries internationally. David has an honours degree in Applied Biological Science from Bristol Polytechnic, specialising in microbiology, and an Executive MBA from the Australian Graduate School of Management.

David has held a number of senior roles within GE Healthcare (Ultrasound and Clinical Systems Services), Recall Corporation (a division of Brambles Industries Limited) and Cobe Laboratories. His various roles covered P&L responsibility, business development, operations and regulatory functions. David has driven global expansion into China, India and Japan and was responsible for the acquisition and integration of four businesses in the Asian region.

The Board focussed its search on a CEO with strong marketing and business skills to complement the world-class research, development and manufacturing divisions of Nanosonics. David Radford's extensive experience in driving rapid growth in the ultrasound device market ideally supports the Company's roll-out of its launch ultrasound disinfection device, based on its proprietary NanoNebulant™ technology. The Company is on track to commence manufacturing of its ultrasound disinfection device in the fourth quarter of calendar 2008.

The Board wishes to express its gratitude to Dr David Fisher who took up the role of interim executive director in December 2007 and to Chris Grundy, CFO, for acting as interim CEO. During this period, the Company successfully achieved the pivotal CE Mark approval for its launch device and successfully commissioned the crucial tooling program which underpins its manufacturing roll-out.

The Board warmly welcomes David and acknowledges his substantial global experience in the medical device market. Under David's leadership, the Company will continue to build strategic partnerships and exploit the many opportunities it has to assert global leadership in healthcare applications and beyond.

Maurie Stang
Chairman

For more information please contact:
Mr Chris Grundy, Chief Financial Officer, on 61-2-8063 1600
or visit www.nanosonics.com.au.



About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.